Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
- 2012 (32) (remove)
Document Type
- Doctoral Thesis (32) (remove)
Language
- English (32) (remove)
Keywords
- Drosophila (4)
- Taufliege (4)
- Apoptosis (3)
- Melanom (3)
- Myc (3)
- Vaccinia-Virus (3)
- oncolytic virotherapy (3)
- onkolytische Virotherapie (3)
- vaccinia virus (3)
- Apoptose (2)
- Ausbreitung (2)
- Evolution (2)
- Geruchssinn (2)
- Hey (2)
- Knockout <Molekulargenetik> (2)
- Learning (2)
- Lernen (2)
- MAP-Kinase (2)
- Molekulargenetik (2)
- Netzwerkanalyse (2)
- Onkolyse (2)
- Sinnesphysiologie (2)
- Systembiologie (2)
- Thrombozyt (2)
- dispersal (2)
- melanoma (2)
- AMP (1)
- AMPK (1)
- Actin nucleation (1)
- Actin-bindende Proteine (1)
- Aktinnukleation (1)
- Alzheimer Dementia (1)
- Alzheimer-Krankheit (1)
- Ameisen (1)
- Amyloid <beta-> (1)
- Aneuploidie (1)
- Anoikis (1)
- Anthrax toxin (1)
- Anämie (1)
- Areal (1)
- BRAF (1)
- Bacillus anthracis (1)
- Black lipid bilayer (1)
- Blochmannia (1)
- Blutbildendes Gewebe (1)
- Blutplättchen (1)
- Bre (1)
- Bre-knockout (1)
- Camponotus (1)
- Circadian Rhythms (1)
- Circadiane Rhythmik (1)
- Cortison (1)
- DNA Reparatur (1)
- DNA repair (1)
- DNS-Reparatur (1)
- Database (1)
- Datenbank (1)
- Datenbanksystem (1)
- Decision-making (1)
- Diabetes mellitus (1)
- Duftintensität (1)
- ERK signaling (1)
- Eierstockkrebs (1)
- Embryonale Stammzelle (1)
- Embryonalentwicklung (1)
- Endogenous Glucocorticoids (1)
- Entscheidung (1)
- Epigenese (1)
- Epigenetic (1)
- Erythropoietin (1)
- Extrazelluläre Matrix (1)
- Fanconi Anemia (1)
- Fanconi Anämie (1)
- Fluoreszenzmikrosopie (1)
- Functional interaction (1)
- Functional module search (1)
- Funktionelle Modulsuche (1)
- GATA4 (1)
- Gedächtnis (1)
- Gen (1)
- Gen notch (1)
- Genregulation (1)
- Geschmack (1)
- Geschmackssinn (1)
- Gesundheitswesen (1)
- Gliom (1)
- Glioma (1)
- Herbivor-Parasitoid Interaktion (1)
- Herz (1)
- Herzentwicklung (1)
- Hochauflösendes Verfahren (1)
- Humorale Immunität (1)
- Insulinrezeptor (1)
- Insulinsignalweg (1)
- Integrated Knowledgebase (1)
- Integrated network analysis (1)
- Integrierte Datenbank (1)
- Interaktion (1)
- Intrazelluläre Symbiose (1)
- Invasion (1)
- Japankärpfling (1)
- Kerntransport (1)
- Knorpelzelle (1)
- Kombinationstherapie (1)
- Krebs <Medizin> (1)
- Land use (1)
- Landnutzung (1)
- Landschaft (1)
- Lin9 (1)
- Lipidmembran (1)
- Lungenkrebs (1)
- MAP3K4 (1)
- MYC (1)
- Management System (1)
- Management-Systeme (1)
- Mass Isotopomers Distribution Analysis (1)
- Massen-Isotopomer Verteilungs-Analyse (1)
- Maus (1)
- Memory (1)
- Messenger-RNS (1)
- Metabolic Flux Analysis (1)
- Metabolische Flux-Analyse (1)
- Metastase (1)
- Microarray (1)
- Mitose (1)
- Miz1 (1)
- Modell (1)
- Nervendegeneration (1)
- Network Analysis (1)
- Netzwerkalgorithmen (1)
- Neurobiologie (1)
- Neurodegeneration (1)
- Next generation sequencing (1)
- Nicht-kleinzelliges Bronchialkarzinom (1)
- Non-Small Cell Lung Cancer (1)
- Odour Intensity (1)
- Olfaction (1)
- Olfactory (1)
- Ovarialkarzinom (1)
- Ovarian Cancer (1)
- PALM (1)
- Parasit (1)
- Perception (1)
- Persistenz (1)
- Phosphoproteomic analysis (1)
- Photorezeption (1)
- Physiology (1)
- Platelets (1)
- Plättchennetzwerk (1)
- Plättchenphosphoproteom (1)
- Polyomaviren (1)
- Polyomavirus JC (1)
- Pore (1)
- Porenbildung (1)
- Protein p53 (1)
- Proteinkinasen (1)
- Proteomanalyse (1)
- Proteome (1)
- Prozessierung (1)
- QDTI (1)
- Repression <Genetik> (1)
- Rho (1)
- Rüsselkäfer (1)
- SWI/SNF (1)
- Sensory (1)
- Signalkette (1)
- Similarity (1)
- Simkania Negevensis (1)
- Simulation (1)
- Software (1)
- Spezialisierung (1)
- Spir (1)
- Spitzwegerich (1)
- Stat5 (1)
- Stoffwechsel (1)
- Strahlentherapie (1)
- Sumo (1)
- Sumoylierung (1)
- Synapse (1)
- Systems Biology (1)
- TNF-R1 (1)
- TNF-R2 (1)
- Taste (1)
- Therapie (1)
- Tiergesellschaft (1)
- Toxin (1)
- Translokation (1)
- Tumor-Nekrose-Faktor <alpha> (1)
- Vaccinia Virus Replikation (1)
- Verbreitungsgrenzen (1)
- Verhalten (1)
- WISP1/CCN4 (1)
- Wahrnehmung (1)
- Zeitdifferenzierung (1)
- Zelladhäsion (1)
- Zelldifferenzierung (1)
- amyloid beta (1)
- anemia (1)
- aneuploidy (1)
- anoikis (1)
- ants (1)
- apoptosis (1)
- arf (1)
- c-myc (1)
- cell adhesion (1)
- combination therapy (1)
- dSTORM (1)
- defective Mitosis (1)
- differentiation (1)
- embryonic stem cells (1)
- erythropoietin (1)
- evolution (1)
- fehlerhafte Mitose (1)
- heart development (1)
- herbivore-parasitoid interaction (1)
- individual-based simulation (1)
- insect immunity (1)
- insulin pathway (1)
- insulin receptor (1)
- interacting species (1)
- interaction (1)
- interaktive Arten (1)
- ionizing radiation (1)
- knock-out mouse (1)
- landscape (1)
- lung cancer (1)
- mRNA processing (1)
- malignant melanoma (1)
- medaka (1)
- mesenchymal stem cells (1)
- mesenchymale Stammzellen (1)
- microRNA (1)
- microarray (1)
- neuronal differentiation (1)
- neuronale Differenzierung (1)
- nuclear transport (1)
- oncolytic therapy (1)
- p53 (1)
- persistierende Infektion (1)
- pore formation and translocation (1)
- range formation (1)
- ribwort plantain (1)
- specialization (1)
- sptPALM (1)
- sumo (1)
- sumoylation (1)
- symbiosis (1)
- type 2 diabetes mellitus (1)
- vaccinia virus replication (1)
- Ähnlichkeit (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (32) (remove)
In this thesis the Drosophila mutant loechrig (loe), that shows progressive degeneration of the nervous system, is further described. Loe is missing a neuronal isoform of the protein kinase AMPK γ subunit (AMP-activated protein kinase- also known as SNF4Aγ) The heterotrimeric AMPK controls the energy level of the cell, which requires constant monitoring of the ATP/AMP levels. It is activated by low energy levels and metabolic insults like oxygen starvation and regulates multiple important signal pathways that control cell metabolism. Still, its role in neuronal survival is unclear. One of AMPK’s downstream targets is HMGR (hydroxymethylglutaryl-CoA- reductase), a key enzyme in cholesterol and isoprenoid synthesis. It has been shown that manipulating the levels of HMGR affects the severity of the neurodegenerative phenotype in loe. Whereas the regulatory role of AMPK on HMGR is conserved in Drosophila, insects cannot synthesize cholesterol de novo. However, the synthesis of isoprenoids is a pathway that is evolutionarily conserved between vertebrates and insects. Isoprenylation of target proteins like small G-proteins provides a hydrophobic anchor that allows the association of these proteins with membranes and following activation. This thesis shows that the loe mutation interferes with the prenylation of Rho1 and the regulation of the LIM kinase pathway, which plays an important role in actin turnover and axonal outgrowth. The results suggest that the mutation in LOE, causes hyperactivity of the isoprenoid synthesis pathway, which leads to increased farnesylation of RHO1 and therefore higher levels of phospho-cofilin. A mutation in Rho1 improves the neurodegenerative phenotype and life span. The increased inactive cofilin amount in loe leads to an up regulation of filamentous actin. Actin is involved in neuronal outgrowth and experiments analyzing loe neurons gave valuable insights into a possible role of AMPK and accordingly actin on neurite growth and stability. It was demonstrated that neurons derived from loe mutants exhibit reduces axonal transport suggesting that changes in the cytoskeletal network caused by the effect of loe on the Rho1 pathway lead to disruptions in axonal transport and subsequent neuronal death. It also shows that actin is not only involved in neuronal outgrowth, its also important in maintenance of neurons, suggesting that interference with actin dynamics leads to progressive degeneration of neurons. Together, these results further support the importance of AMPK in neuronal function and survival and provide a novel functional mechanisms how alterations in AMPK can cause neuronal degeneration
Cancer-related anemia is prevalent in cancer patients. Anemia negatively affects normal mental and physical function capacity with common symptoms s like fatigue, headache, or depression. Human erythropoietin (hEPO), a glycoprotein hormone regulating red blood cell formation, is approved for the treatment of cancer-related anemia. It has shown benefits in correcting anemia, and subsequently improving health-related quality of life and/or enhancing radio-, and chemotherapy. Several recent clinical trials have suggested that recombinant hEPO (rhEPO) may promote tumor growth that raises the questions concerning the safety of using rhEPO for cancer treatment. However in others, such effects were not indicated. As of today, the direct functional effect of rhEPO in tumor models remains controversial and needs to be further analyzed. Based on the GLV-1h68 backbone, the hEPO-expressing recombinant VACV strains (EPO-VACVs) GLV-1h210, GLV-1h211, GLV-1h212 and GLV-1h213 were generated by replacing the lacZ expression cassette at the J2R locus with hEPO under the control of different vaccinia promoters p7.5, pSE, pSEL, pSL, respectively. Also, GLV-1h209 was generated, which is similar to GLV-1h210 but expresses a mutated non-functinal EPO (R103A). The EPO-VACV strains were characterized for their oncolytic efficacy in lung (A549) cancer cells in culture and tumor xenografts. Concomitantly, the effects of locally expressed hEPO in tumors on virus replication, host immune infiltration, tumor vascularization and tumor growth were also evaluated. As expected, EPO-VACVs enhanced red blood cell (RBC) formation in xenograft model. The number of RBCs and hemoglobin (Hb) levels were significantly increased in EPO-VACVs-treated mice compared to GLV-1h68-treated or untreated control mice. However, the mean size of RBC or Hb content per RBC remained normal. Furthermore, over-expression of hEPO did not significantly affect numbers of lymphocytes, monocytes, leucocytes or platelets in the peripheral blood stream. The expression of hEPO in colonized tumors of mice treated with EPO-VACVs was demonstrated by immunohistological staining. Interestingly, there were 9 - 10 hEPO isoforms detected either in tumors, cells, or supernatant, while 3-4 basic isoforms were missing in blood serum, where only six hEPO isoforms were found. Tumor-bearing mice after treatment with EPO-VACVs showed enhanced tumor regression compared to GLV-1h68. The virus titers in tumors in EPO-VACVs-treated mice were 3-4 fold higher compared to GLV-1h68-treated mice. Nevertheless, no significant difference in virus titers among EPO-VACVs was found. The blood vessels in tumors were significantly enlarged while the blood vessel density remained unchanged compared to the GLV-1h68 treated mice, indicating that hEPO did not affect endothelial cell proliferation in this model. Meanwhile, rhEPO (Epoetin alfa) alone or in combination with GLV-1h68 did not show any signs of enhanced tumor growth when compared to untreated controls and GLV-1h68 groups, while doses used were clinical relevant (500 U/kg). These findings suggested that hEPO did not promote angiogenesis or tumor growth in the A549 tumor xenograft model. Human EPO has been reported to function as an immune modulator. In this study, however, we did not find any involvement of hEPO in immune cytokine and chemokine expression or innate immune cell infiltration (leucocytes, B cells, macrophages and dendritic cells) into infected tumors. The degree of immune infiltration and cytokine expression was directly correlated to the number of virus particles. Increased virus replication, led to more recruited immune cells and secreted cytokines/chemokines. It was proposed that tumor regression was at least partially mediated through activation of innate immune mechanisms. In conclusion, the novel EPO-VACVs were shown to significantly increase the number of RBCs, Hb levels, and virus replication in tumors as well as to enhance tumor regression in the A549 tumor xenograft model. Moreover, locally expressed hEPO did not promote tumor angiogenesis, tumor growth, and immune infiltration but was shown to causing enlarged tumoral microvessels which facilitated virus spreading. It is conceivable that in a possible clinical application, anemic cancer patients could benefit from the EPO-VACVs, where they could serve as “wellness pills” to decrease anemic symptoms, while simultaneously destroying tumors.